Who are NOV03's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VALACYCLOVIR, intravenous (IV) ganciclovir, Acyclovir (ACV), Masked Oral Valacyclovir, Valacyclovir (ZELITREX), Placebo to ACV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nov03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

NOV03 — Competitive Intelligence Brief

NOV03 (NOV03) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nucleoside analog. Area: Infectious Diseases.

phase 3 nucleoside analog viral DNA polymerase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

NOV03 (NOV03) — Bausch & Lomb Incorporated. NOV03 is an investigational antiviral medication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NOV03 TARGET	NOV03	Bausch & Lomb Incorporated	phase 3	nucleoside analog	viral DNA polymerase
VALACYCLOVIR	VALACYCLOVIR		marketed	Nucleoside analogue	Viral DNA polymerase	1995-01-01
intravenous (IV) ganciclovir	intravenous (IV) ganciclovir	University of Oslo School of Pharmacy	marketed	Nucleoside analog antiviral	Viral DNA polymerase (CMV and herpes simplex virus)
Acyclovir (ACV)	Acyclovir (ACV)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpes simplex virus and varicella-zoster virus)
Masked Oral Valacyclovir	Masked Oral Valacyclovir	NYU Langone Health	marketed	Nucleoside analog antiviral	Viral DNA polymerase (HSV and VZV)
Valacyclovir (ZELITREX)	Valacyclovir (ZELITREX)	Assistance Publique - Hôpitaux de Paris	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpesvirus)
Placebo to ACV	Placebo to ACV	Merck Sharp & Dohme LLC	phase 3	Nucleoside analog antiviral	Viral DNA polymerase (HSV/VZV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nucleoside analog class)

Atea Pharmaceuticals, Inc. · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Medivir · 1 drug in this class
Tarapeutics Science Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NOV03 — Competitive Intelligence Brief. https://druglandscape.com/ci/nov03. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab